-
The optimal duration for dual anti-platelet therapy (DAT) after drug-eluting stent (DES) implantation remains unknown.
-
Yu et al report a multi-center trial evaluating the relative benefits of right ventricular apical pacing compared to biventricular pacing in patients with a standard indication for pacing and a baseline preserved left ventricular ejection fraction.
-
Statin and niacin increase HDL-C, omeprazole reduces effectiveness of clopidogrel, darbe-poetin increases risk of stroke, statins decrease risk of gallstone disease, FDA Actions
-
Anticoagulation during percutaneous coronary intervention (PCI), although necessary to prevent thrombus formation on the interventional equipment, can lead to significant morbidity from bleeding complications, particularly if the dosage is excessive.
-
Intensive lipid lowering with statin therapy (atorvastatin 80 mg) in patients presenting with acute coronary syndromes (ACS) resulted in improved outcomes compared to treatment with moderate lipid lowering (pravastatin 40 mg) in the PROVE-IT TIMI-22 study (Cannon et al. N Engl J Med.
-
Two recent studies have demonstrated the bene-ficial effects of nicotinic acid (niacin) on carotid artery atherosclerosis.
-
-
Coronary revascularization without cardiopul-monary bypass has become quite successful, in part because of the belief that off-pump coronary bypass procedures are safer than on-pump surgery.
-
The ventricular tachycardia ablation in coronary Heart Disease (VTACH) study tested the hypothesis that mapping and prophylactic catheter ablation of ventricular tachycardia prior to implantable cardioverter defibrillator (ICD) insertion in patients with hemodynamically stable ventricular tachycardia (VT) would improve clinical outcomes.
-
In this paper, Dhruva et al examine the types of studies that were involved in premarket approval (PMA) of cardiovascular devices by the FDA over a seven-year period.
